As of June 16, 2025, Sartorius Stedim Biotech SA (DIM.PA) reports a EV/EBITDA of 30.43.
EV/EBITDA evaluates a company's total value relative to its earnings before interest, taxes, depreciation, and amortization, useful for comparing firms with different capital structures.
Comparing Sartorius Stedim Biotech SA's EV/EBITDA to Peers
To better understand Sartorius Stedim Biotech SA's position, it's useful to compare its EV/EBITDA against industry peers. Below are selected comparisons:
| Company | EV/EBITDA |
|---|---|
| Sartorius Stedim Biotech SA (DIM.PA) | 30.43 |
| Repligen Corp (RGEN) | 118.66 |
| Lonza Group AG (LONN.SW) | 40.52 |
| Chemometec A/S (CHEMM.CO) | 39.26 |
| Qiagen NV (QGEN) | 36.19 |
| Bio-Techne Corp (TECH) | 29.01 |
Compared to its competitors, Sartorius Stedim Biotech SA's EV/EBITDA is among the highest compared to peers, suggesting the market values the company at a premium, possibly due to growth expectations.